A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 25 Sep 2018
At a glance
- Drugs TAK 079 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.
- 16 Apr 2018 Planned initiation date changed from 20 Mar 2018 to 1 May 2018.
- 13 Mar 2018 Planned initiation date changed from 19 Feb 2018 to 20 Mar 2018.